December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Diabetes-Induced Retinal Vascular Permeability is Reversed by Intravitreal Injection of Pigment Epithelial Derived Factor
Author Affiliations & Notes
  • HI Salti
    Beetham Eye Institute Joslin Diabetes Center Boston MA
  • AC Clermont
    Beetham Eye Institute Joslin Diabetes Center Boston MA
  • E Duh
    Willmer Ophthalmological Institute Johns Hopkins University and Hospital Baltimore MD
  • L Goddard
    Beetham Eye Institute Joslin Diabetes Center Boston MA
  • LP Aiello
    Beetham Eye Institute Joslin Diabetes Center Boston MA
  • Footnotes
    Commercial Relationships   H.I. Salti, None; A.C. Clermont, None; E. Duh, None; L. Goddard, None; L.P. Aiello, None. Grant Identification: EY10827 & RPB DOLLY GREEN SCHOLARSHIP
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3864. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      HI Salti, AC Clermont, E Duh, L Goddard, LP Aiello; Diabetes-Induced Retinal Vascular Permeability is Reversed by Intravitreal Injection of Pigment Epithelial Derived Factor . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3864.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Previously, we demonstrated that Pigment Epithelial Derived Factor (PEDF) blocks VEGF-induced retinal vascular permeability in vivo in a dose dependent manner. Since an increase in VEGF expression and retinal vascular leakage is associated with diabetic retinopathy and diabetic macular edema, we investigated whether exogenously added PEDF could inhibit diabetes-induced retinal vascular permeability. Methods: Retinal vascular leakage in non-diabetic and STZ-induced diabetic Sprague-Dawley rats was measured by the Evans Blue albumin permeation technique. At days 11 and 13 after induction of diabetes, 10 ul of PEDF (200 ng/eye, 40nM final) was injected into one eye and vehicle (0.1% BSA in PBS) was injected into the contralateral eye under sterile conditions. The intact condition of each eye and retina was assessed 24 hours after each injection. At day 14, the animals were sacrificed and retinal vascular permeability was determined. Results: Vascular leakage was increased by 79% (p=0.026) in diabetic rats (7.7±3.4, n=11) as compared with non-diabetic rats (4.3±1.6, n=7). PEDF suppressed diabetes-induced retinal vascular leakage by 88% (4.7±3.8, n=7, p=0.031). Vascular permeability was not significantly altered in non-diabetic rats treated with PEDF (3.7±1.0, n=7). Conclusion: Intravitreal injection of PEDF significantly normalized diabetes-induced retinal vascular leakage within three days even after eleven days of diabetes. Durability of this effect is under investigation. These data suggest that PEDF may have significant therapeutic potential for the treatment of diabetic macular edema and other VEGF-related disorders.

Keywords: 316 animal model • 423 growth factors/growth factor receptors • 388 diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×